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Inﬂammation when unchecked is associated with many prevalent
disorders such as the classic inﬂammatory diseases arthritis
and periodontal disease, as well as the more recent additions
that include diabetes and cardiovascular maladies. Hence
mechanisms to curtail the inﬂammatory response and pro-
mote catabasis are of immense interest. In recent years, evidence
has prompted a paradigm shift whereby the resolution of acute
inﬂammationisabiochemicallyactiveprocessregulatedinpartby
endogenousPUFA(polyunsaturatedfattyacid)-derivedautacoids.
AmongtheseareanovelgenusofSPMs(specializedproresolving
mediators) that comprise novel families of mediators including
lipoxins, resolvins, protectins and maresins. SPMs have distinct
structures and act via speciﬁc G-protein seven transmembrane
receptors that signal intracellular events on selective cellular
targets activating proresolving programmes while countering
pro-inﬂammatory signals. An appreciation of these endogenous
pathways and mediators that control timely resolution opened a
new terrain for therapeutic approaches targeted at stimulating
resolution of local inﬂammation. In the present review, we
provide an overview of the biosynthesis and actions of resolvin
E1, underscoring its protective role in vascular systems and
regulating platelet responses. We also give an overview of newly
described resolution circuitry whereby resolvins govern miRNAs
(microRNAs), and transcription factors that counter-regulate pro-
inﬂammatory chemokines, cytokines and lipid mediators.
Key words: lipid mediator, microRNA, omega-3 fatty acid,
platelet, resolution.
HOMOEOSTASIS: THE PUSH AND PULL OF PRO-INFLAMMATORY
AND PRORESOLVING MEDIATORS
Oedema formation and leucocyte emigration are essential com-
ponents of the acute inﬂammatory response [1] (Figure 1A). Ini-
tiallyprotective,acuteinﬂammationisaphysiologicalprogramme
that protects the host against invading pathogens and local injury
[1]. If uncontrolled, inﬂammation can become chronic leading to
ﬁbrosis and tissue damage. A prominent cause of tissue damage
is excessive leucocyte accumulation as in the cases of arthritis
or periodontal disease [2]. Hence, mechanisms for removal of
leucocytes from inﬂammatory sites and the clearance of remnants
of the host’s combat between leucocytes, invading microbes,
and/orotherinitiatorsofinﬂammationareofconsiderableinterest.
It is becoming increasingly apparent that the resolution of
inﬂammation and the return from disease state (catabasis)
requires active counter-regulation of pro-inﬂammatory signals
[3]. Counter-regulation of the inﬂammatory response is achieved
by several physiological mechanisms acting at the systemic
level; biosynthesis of local bioactive lipid autacoids, an increase
in circulating levels of glucocorticoids, or activation of the
acute-phase response, provide systemically active and protective
responsestostressandinﬂammation.Withinthevasculatureasan
example, AA (arachidonic acid)-derived PGI2 (prostacyclin) and
TX (thromboxane) A2 are important counter-regulators whereby
both chemical mediators are necessary for vascular homoeostasis
[4].
Resolution of inﬂammation is operative at the local tissue level
to limit inﬂammatory injury and restore homoeostasis [5]. In
addition to AA-derived lipoxins, a novel genus of enzymatically
oxygenated lipid mediators derived from ω – 3 PUFAs (poly-
unsaturated fatty acids), such as EPA (eicosapentaenoic acid) and
DHA (docosahexaenoic acid), were elucidated in this laboratory
that function as SPMs (specialized proresolution mediators) that
actively ‘turn off’ the inﬂammatory response [6]. These SPM
families include lipoxins, resolvins, protectins and maresins
(Figure 1B) and comprise novel families of autacoids with potent
anti-inﬂammatory, tissue-protective and resolution-stimulating
functions[6].Ofnote,eachSPMhasauniquestructuralfeatureto
evoke biological functions. The biosynthesis and general actions
were recently reviewed in detail in [7,8].
The formation of speciﬁc lipid mediator autacoids during
resolutionwasmonitoredbyLC-MS/MS(liquidchromatography-
tandem MS)-based lipidomic analysis of resolving, self-limited
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Figure 1 Acute inﬂammation cellular and chemical mediators
(A) At the onset of acute inﬂammation, vascular leakage (oedema) occurs. Neutrophils are among the ﬁrst responders during an acute inﬂammatory response, followed by monocytes and
macrophages. The ﬁrst cellular hallmark of tissue resolution is a decrease in neutrophil inﬁltration. Updated from [1]. Classically, eicosanoids such as PGE2,T X A 2 and LTB4 (B, red) are known to
exert pro-inﬂammatory actions such as vasodilatation, platelet activation and chemotaxis respectively. Proresolving molecules are generated during inﬂammation that block vasodilatation/oedema
formationandlimitfurtherchemotaxisthusallowingforthereturntohomoeostasis.(B,blue)(B)SchemeofeicosanoidandSPMgeneration.AA-derivedeicosanoidsareinred.EPA-derivedE-series
resolvins, DHA-derived D-series resolvins, protectins and maresins are in blue.
inﬂammatory exudates. The biosynthesis with human cells
was assembled employing individual cell types and human
recombinantenzymes[9]usingasystemsapproachwithexudates
from experimental animals (reviewed in detail in [6]).
SPMs regulate homoeostasis
The ﬁrst anti-inﬂammatory and proresolving SPMs recognized
were LX (lipoxin) A4 and LXB4 [10]. Lipoxins are lipoxygenase-
derived eicosanoids, derived enzymatically from AA, an ω –6
fatty acid that is released and mobilized during inﬂammation
[11]. In human systems, they are synthesized via transcellular
biosynthesis steps engaged during leucocyte interactions with
mucosal cells, that is, epithelia of the gastrointestinal tract or
bronchial tissue, and within the vasculature during platelet–
leucocyte interactions [6] (For further details regarding protective
action in vivo, see Table 1). Aspirin has an unexpected impact
within resolution. In humans, aspirin ‘jump-starts’ this process
by its ability to trigger the endogenous biosynthesis of speciﬁc
lipidmediators[10].TheLXswereﬁrstappreciatedfortheiranti-
inﬂammatory actions in vivo, but took nearly two decadesto learn
that they are agonists of resolution [12].
Resolvins are a family of new local mediators enzymatically
generated within resolving inﬂammatory exudates. They were
initially identiﬁed using a systems approach with LC-MS/MS-
based lipidomics and informatics, and subsequently complete
structural elucidation of these bioactive mediators and related
compounds was achieved [13–17]. The term resolvins or
resolution-phase interaction products refers to endogenous
mediators that are biosynthesized from the major ω – 3 fatty
acids EPA and DHA, denoted as E series (RvE) and D series
(RvD) resolvins respectively [6]. Similar to lipoxins, resolvins
are also generated by the COX (cyclo-oxygenase)-2 pathway
in the presence of aspirin yielding ‘AT’ (aspirin-triggered)
forms. Increasing evidence indicates that resolvins possess potent
anti-inﬂammatory and immunoregulatory actions that include
blocking the production of pro-inﬂammatory mediators (i.e.
chemokines and cytokines) and the organized leucocyte trafﬁc
to inﬂammatory sites (reviewed in [18]), as well as clearance of
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Table 1 In vivo actions of lipoxins and aspirin-triggered lipoxins with a LXA4/ATL mediator
Species/disease model Action(s)
Mouse/dermal inﬂammation Inhibits neutrophil recruitment and vascular leakage [103]
Mouse/dorsal air pouch Inhibits neutrophil recruitment [104]
Rabbit/periodontitis Reduces PMN inﬁltration and prevents connective tissue and bone loss
[105]
Mouse/peritonitis Inhibits neutrophil recruitment and lymphatic removal of phagocytes
[3,12]
Mouse/colitis Attenuates pro-inﬂammatory gene expression and reduces severity of
colitis, inhibits weight loss, inﬂammation and immune dysfunction [106]
Mouse/asthma Inhibits airway hyper-responsiveness and pulmonary inﬂammation
[107]
Mouse/cystic ﬁbrosis Decreases neutrophilic inﬂammation, pulmonary bacterial burden and
disease severity [108]
Mouse/ischaemia/reperfusion (I/R) Attenuates hind-limb I/R-induced lung injury [109]. Detachment of
adherent leucocytes in mesenteric I/R [110]. Reduces myocardial
infarct size and area at risk in myocardial I/R (infarction)
Mouse/cornea Accelerates cornea re-epithelialization, limits sequelae of thermal injury
(i.e. neovascularization, opacity) and promotes host defence [86]
Mouse/angiogenesis Reduces angiogenic phenotype: endothelial cell proliferation and
migration [111]
Mouse/bone marrow transplant (BMT) Protects against BMT-induced graft-versus-host diseases (GvHD) [112]
Rat/glomerulonephritis Reduces leucocyte rolling and adherence, decreases neutrophil
recruitment [113]
Rat/hyperalgesia Prolongs paw withdraw latency, reducing hyperalgesic index and
reduces paw oedema [114]
Rat/pleuritis Shortens the duration of pleural exudation [115]
Mouse/tumour growth Suppresses the growth of transplanted H22 tumour in mice through
inhibiting tumour-related angiogenesis [116]
Mouse/allograft rejections Prevents acute rejection of vascularized cardiac and renal allografts
[117]
Mouse/arthritis Inhibits oedema formation and PMN inﬂux, reduces TNFα and LTB4
levels [118]
Rat/acute pancreatitis Reduces intercellular adhesion molecule 1 (ICAM-1) and NF-κB p65
expression in the pancreas, and expression of ICAM-1 in the lungs in
animals with pancreatitis [119]
neutrophilsfrommucosalsurfaces[19].Speciﬁcally,resolvinsare
multi-focal-acting mediators that act via limiting further PMN
(polymorphonuclear cell/neutrophil) transendothelial migration
in vitro and inﬁltration in vivo [13,14], but also enhance
pro-inﬂammatory chemokine scavenging [20], non-phlogistic
recruitmentonmonocytesandphagocytosis,aswellasphagocyte
clearance via the lymphatics [12].
The actions of these endogenous SPMs are mediated
via speciﬁc 7-TMs (G-protein-coupled seven-transmembrane
receptors). Hence, SPMs are resolution agonists that stimulate
proresolving pathways, rather than obstruct anti-inﬂammatory
signals. RvE1 (resolvin E1) as an example, acts as an
agonist on ChemR23 (G-protein-coupled receptor for RvE1)
and as a partial agonist on the LTB4 (leukotriene B4) receptor
(BLT1) thus competing with LTB4 for binding [17,21]. Recent
research has revealed that RvE1 stimulates phosphorylation
of Akt and p70S6K (ribosomal protein S6 kinase) in a
time- and dose-dependent manner via direct activation of
ChemR23 [22]. RvE1 therefore displays a distinct mechanism
of action compared with LXA4 that inhibits downstream tyrosine
phosphorylation in eosinophils [23]. Recently two separate
7-TMsthatRvD1speciﬁcallybindsonhumanleucocytes,namely
the ALX/FPR2 (LXA4 receptor) and GPR32 (G-protein-coupled
receptor for RvD1) an orphan receptor were reported [24].
Identiﬁcation of receptors for the other ω – 3-derived SPMs are
yet to be uncovered, but are likely to also be high-afﬁnity 7-
TMs on the basis of the potency and stereoselective actions
of each SPM member. Hence, two GPCRs for each RvE1 and
RvD1 have been identiﬁed. The notion that one ligand can act
on a repertoire of receptors is not surprising in light of recent
evidence on neuronal responses to formyl receptor-like peptides
that possess ALX/FPR2 and are activated by LXA4 [25]. Also,
anti-inﬂammatory peptides annexin 1 and chemerin speciﬁcally
activate these receptors as well [26].
SPMs are made available to evolving exudates
Early phases of the acute inﬂammatory response involve rapid
changes in local blood vessel perfusion and permeability not
only to permit extravasation of circulating leucocytes and plasma
proteins, but also provide a means to deliver nutrient from the
circulation, namely substrates for exudate SPM biosynthesis.
In zymosan-stimulated peritonitis exudate the levels of free or
unesteriﬁed ω−3 PUFA, AA, EPA and DHA increase rapidly,
reaching maximal levels approximately 2–4 h post-stimulation
[3]. Systemically administered deuterium-labelled ω−3 PUFAs
rapidlyappearinthedevelopinginﬁltratewithintheinﬂammatory
exudatesandasecondwaveofcirculatingsubstratesaredelivered
during resolution [27]. A close inspection indicates that the
SPM precursors EPA and DHA appear in the inﬂammatory
milieu with similar kinetics as the extravasation of serum
proteins (identiﬁed using proteomics [3]), paralleling oedema
yet before the inﬁltration of neutrophils. These ﬁndings point
to the importance of oedema with exudating serum proteins, to
effectivelydeliverω−3PUFAstoaninﬂamedtissueandpromote
resolution.
Withoutcontroloftheinﬂammatoryresponse,tissueswouldbe
overwhelmed by oedema, persistent inﬂammatory cell inﬁltrates
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Table 2 In vivo actions of resolvins, protectins and maresins
Mediator Species/disease model Action(s)
RvE1 Mouse/dorsal air pouch Inhibits neutrophil recruitment [13]
Mouse/peritonitis Inhibits neutrophil recruitment, regulates chemokine/cytokine production [3,17] and promotes lymphatic removal of phagocytes [12]
Rabbit/periodontitis Reduces PMN inﬁltration, prevents connective tissue and bone loss, promotes healing of diseased tissues and promotes regeneration
of lost soft tissue and bone [62,63]
Mouse/retinopathy Protects against neovascularization [120]
Mouse/colitis Decreases PMN recruitment and pro-inﬂammatory gene expression, improves survival and reduces weight loss [64,121]
Mouse/asthma Reduces IL-23 and IL-6, and increases IFNγ and LXA4 in lungs to dampen airway inﬂammation [122].
RvE1 decreases eosinophil and lympocyte recruitment [123,124]
Mouse/obesity Regulates adipokines and protects against liver steatosis [125]
Mouse/inﬂammatory pain Inhibits spontaneous pain, and heat and mechanical hypersensitivity [126]
Rat/cardiac ischaemia/reperfusion injury Reduces infarct size [127]
Mouse/allograft rejections Prevents acute rejection of vascularized cardiac and renal allografts [117]
Mouse/dry eye Promotes tear production, corneal epithelial integrity, and decreases in inﬂammatory inducible COX-2. RvE1 inhibits keratocyte
transformation to myoﬁbroblasts and lowers the number of monocytes/macrophages [65]
Mouse/herpes simplex virus Reduces severity of herpes simplex virus-induced ocular lesions, reduces angiogenesis and stromal keratitis [128]
RvD1 Mouse/peritonitis Inhibits neutrophil recruitment [15,100]
Mouse/dorsal air pouch Inhibits neutrophil recruitment [14,15]
Mouse/kidney ischemia-reperfusion Protects from ischaemia/reperfusion-induced kidney damage and loss of function. Regulates macrophages [129]
Mouse/retinopathy Protects against neovascularization [120]
Mouse/inﬂammatory pain Inhibits spontaneous pain, heat and mechanical hypersensitivity [126]
Rats/post-operative pain Reduces post-operative pain, tactile allodynia and hyperalgesia [130]
PD1/NPD1 Mouse/peritonitis Inhibits neutrophil recruitment and regulates chemokine/cytokine production [3,16]
Promotes lymphatic removal of phagocytes [12] and regulates T-cell migration [131]
Mouse/asthma Protects from lung damage, airway inﬂammation and hyperresponsiveness [132]
Human/asthma PD1 is generated in human asthma [132]
Mouse/kidney ischaemia/reperfusion Protects from ischaemia/reperfusion-induced kidney damage and loss of function; regulates macrophages [129]
Mouse/retinopathy Protects against neovascularization [120]
Rat/ischaemic stroke Inhibits leucocyte inﬁltration, NF-κB and COX-2 induction [133]
Human/Alzheimer’s disease Diminished PD1 production in human Alzheimer’s disease [33]
Mouse/liver injury Protects necroinﬂammatory liver injury [125]
Mouse/Alzheimer’s disease Potently down-regulates inﬂammatory signalling, amyloidogenic amyloid precursor protein cleavage and apoptosis [134]
RvD2 Mouse/peritonitis Potently blocks PMN inﬁltration into the peritoneum [135]
Mouse/sepsis Prevents hypothermia, decreases bacterial load in the blood and peritoneum, promotes survival [135]
MaR1 Mouse/peritonitis Potently blocks PMN inﬁltration into the peritoneum [136]
andsubsequenttissuedamageincurredbyactivatedinﬂammatory
leucocytes[28–30].Thusactivecounter-regulationandresolution
ofinﬂammationareessentialforthemaintenanceofhomoeostasis
and health [31]. This present review focuses on the protective
actions of resolvins, speciﬁcally the ﬁrst elucidated resolvin
denoted RvE1, on selective cellular targets such as platelets,
smooth muscle cells and macrophages, as well as novel concepts
underlying resolution circuitry.
CHANGING THE PARADIGM FOR ω−3 FATTY ACID PROTECTION IN
HUMAN PATHOLOGIES: FOCUS ON CARDIOVASCULAR DISEASE
Essential fatty acids, such as EPA and DHA, are well known for
their protective actions in many diseases including, cancer [32],
Alzheimer’s disease [33] and cardiovascular diseases [34–38].
Their cardioprotective actions were ﬁrst observed in the 1970s
[39–43].
Dyerberg et al. [44] demonstrated that in the presence of
EPA, the formation of TXA3 catalysed by platelet endoperoxides
[45], which is mainly driven by COX-1. Unlike AA-derived
TXA2 which is a potent platelet agonist [46], TXA3 does not
have platelet-aggregating properties. AA and EPA can both be
utilized by COX-1 to generate the intermediate endoperoxide and
subsequent TXA2 or TXA3 respectively, creating a competition
between these substrates for the enzyme [47,48]. In a milieu
enriched in EPA, the COX-1 appears to favour EPA over utilizing
AA as a substrate generating the biologically inactive TXA3 [44].
Moreover, EPA can be utilized by the endothelium to make an
anti-aggregating substance, PGI3 ( 
17-prostacyclin) [44,48]. This
ﬁnding suggests that, in vivo, high levels of EPA and low levels
of AA could lead to an anti-thrombotic state that is mediated by
PGI3 and a non-active TXA3 [44]. Thus utilization of EPA rather
than AA in vivo would presumably shift the balance between
the pro- and anti-aggregating (i.e. TXA2/PGI2) agents toward the
anti-aggregatory (TXA3/PGI3) [44,49,50].
The GISSI (Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico) study demonstrated reduced mortality
from cardiovascular complications (e.g. cardiac death and
coronary death) in >11000 cardiovascular patients taking ω−3
PUFAs [51,52]. It is noteworthy that, given the cardiovascular
status of these patients, all were taking aspirin [51,52]. Aspirin
is one of the most widely used anti-inﬂammatory drugs, and
low-dose aspirin (81 mg) is currently recommended by the
American Heart Association (http://www.americanheart.org) for
both primary and secondary prevention of myocardial infarction,
stroke and unstable angina. The beneﬁcial actions of aspirin
in the cardiovascular system have been widely attributed to
the well-documented ability of aspirin to block prostaglandins
and prothrombotic TXA2 generation via acetylation of COX-1
[53,54].Notably,aspirinhasadditionalanti-inﬂammatoryactions,
such as blocking leucocyte trafﬁcking to inﬂamed tissues, which
cannot only be attributed to aspirin’s ability to inhibit prostanoid
biosynthesis [18,55]. As noted above, aspirin acetylation of
COX-2 not only inhibits prostanoid formation, but alters the
active site of COX-2 and thereby permits conversion of AA into
15R-HETE (hydroxyeicosatetraenoic acid) or EPA to 18-HEPE
in vascular endothelial cells as examples. These intermediates
c   The Authors Journal compilation c   2011 Biochemical Society © 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Cellular and molecular targets resolving inﬂammation 189
Figure 2 RvE1 has potent and stereoselective action on human platelets
(A) RvE1(grey) andits stableisomer 19-para-ﬂuorophenoxy-RvE1(black) bothreducedADP-stimulated platelet aggregation.Thebiologicallyinactiveisomer ofRvE1, 6,14-trans isomer (red)did
not block ADP-stimulated platelet aggregation. (B) Representative real-time aggregation tracings for  6,14-trans isomer (left-hand panel) and 19-para-ﬂuorophenoxy-RvE1 (right-hand panel).
can be further transformed to epimeric lipoxins, RvE1, or
aspirin-triggered resolvins by leucocytes [6]. The formation
of 15-epi-lipoxins, as an example, is documented in healthy
individuals taking low-dose aspirin and is shown to be both age
and gender dependent [56,57]. Recently, the anti-inﬂammatory
actions of aspirin were documented during acute inﬂammation in
humans [58,59]. Oral administration of low-dose aspirin reduced
leucocyte accumulation in cantharidin-induced skin blisters and
stimulated both 15-epi-lipoxin biosynthesis and an increase in
ALX expression [58].
Hence, recent evidence now points to bioactive lipid mediators
that are structurally distinct and act via speciﬁc 7-TMs to actively
counter-regulate pro-inﬂammatory signals. The next sections
highlight the biosynthesis, structural elucidation and the targeted
cellular actions of EPA-derived RvE1.
RvE1 BIOSYNTHETIC ROUTES AND SELECTIVE CELLULAR ACTIONS
RvE1 biosynthesis and structural elucidation
RvE1 is generated by human cell types during cell–cell
interactions from EPA typiﬁed by endothelial cell and leucocyte
interaction [13]. In vascular endothelial cells, aspirin-acetylated
COX-2 converts EPA into 18R-hydro(peroxy)-EPE, which is
quickly reduced to 18R-HEPE. 18R-HEPE is then released
from endothelium and rapidly transformed by activated human
PMNs in the proximity to a bioactive trihydroxy-containing
product, termed RvE1 that reduced PMN transmigration
and was anti-inﬂammatory in vivo more than 100× more
potent than aspirin or dexamethasone [17]. Total organic
synthesis conﬁrmed the original structural assignment and
bioactions as well as established the complete stereochemistry
of natural RvE1,5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-
EPA [17]. RvE1 is also produced in vivo through aspirin-
independent routes via mechanisms involving P450 [60] and
was also found to be produced by Candida albicans [61]. Thus
there are multiple biosynthetic pathways for RvE1 production in
biologicalsystems, thosebeingaspirintriggered,P450dependent
and/or de novo from microbial sources. RvE1 has protective
actions in preclinical animal models of disease including
experimental periodontitis [62,63], colitis [64] and dry eye [65]
to name a few (see Table 2 for details). RvE1 also has actions on
several cell types including leucocytes and platelets [66].
RvE1 actions in human whole blood, platelets and smooth muscle
cells
EPA-derived RvE1 is endogenously generated in whole blood
[17] and selectively acts on PMNs and monocytes to reduce
L-selectinandCD(clusterofdifferentiation)18surfaceexpression
[66]. Corroborating results via intravital microscopy in mice
also demonstrated that RvE1 reduced leucocyte rolling along
the endothelium. Additionally, RvE1 stimulation of whole blood
regulated various cytokines and chemokines. Notably, RvE1
reduced IL (interleukin)-8 and increased IL-10 levels in human
whole blood [66].
Platelets are critical in coagulation, atherogenesis, wound
healing and inﬂammation. Platelet–platelet interactions are
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essential in thrombosis, which has further consequences on
platelet–leucocyte and platelet–endothelium interactions [67].
These active cell–cell communications are responsible for and
provide the links between thrombosis, inﬂammation and athero-
genesis [68,69]. In view of the beneﬁcial impact of EPA and
aspirin in the cardiovascular arena, it was of particular interest to
investigatewhetherRvE1directlyactsonhumanplatelets.Indeed,
EPA-derived RvE1 reduced ADP-stimulated platelet aggregation
and TX generation [66]. In addition to ADP, RvE1 also reduced
plateletaggregationstimulatedbyU46619,aTXreceptoragonist,
with similar kinetics [66]. In contrast, RvE1 did not affect
collagen-stimulated platelet aggregation, indicating an agonist-
selective action of RvE1 on human platelet aggregation. PD1
(protectin D1) reduces ADP-stimulated platelet aggregation in
the micromolar range [66]. Of interest, newly named DHA-
derived products coined poxytrins block collagen-stimulated
platelet aggregation, but require micromolar concentrations for
their actions [70,71]. The vital platelet homoeostatic responses
(e.g. collagen- and thrombin-induced aggregation for wound
healing) of poxytrins in the micromolar range raise the question
regarding their physiological role in humans.
ChemR23, one of the receptors for RvE1, is present on human
platelets [66,72] and to address whether RvE1’s actions on
platelets were stereoselective, RvE1 was directly compared with
its biologically inactive isomer, the  6, 14-trans RvE1 isomer
[17] and it biologically stable isomer 19-para-ﬂuorophenoxy
RvE1 (Figure 2). RvE1 and 19-para-ﬂuorophenoxy RvE1
markedly reduced ADP-stimulated platelet aggregation, whereas
RvE1’s biologically isomer  6,14-trans RvE1 did not in
this concentration range (Figure 2), this family demonstrated
a selective action for RvE1 in attenuating human platelet
aggregation in PRP (platelet-rich plasma).
The actions of ADP on platelets are of particular interest
because ADP is a well appreciated local mediator of haemostasis
and thrombosis, and when aberrantly regulated can contribute
to the pathogenesis of cardiovascular diseases [4,73]. On
platelets, ADP speciﬁcally binds and activates two G-protein-
coupled receptors P2Y1 and P2Y12. Transduction of the ADP
signal involves inhibition of adenyl cyclase (via P2Y12)a n d
a concomitant transient increase of intracellular Ca
2+ (via
P2Y1) [73]. Further downstream signalling results in robust
shape changes, inside-out activation of platelet receptors, such
as GPIIbIIIa, and granule secretion [73]. Current anti-platelet
therapies targeted at blocking purinergic receptor signalling,
speciﬁcally P2Y12 antagonists, are the focal point of platelet
therapeutics [74] and are among the most widely used
pharmacotherapy in cardiovascular diseases [75,76].
RvE1 and its 19-para-ﬂuorophenoxy-RvE1 analogue are more
potent than the native EPA, and limited ADP-stimulated P-
selectin surface mobilization [72]. Additionally RvE1 dampened
the potentiation of ADP-stimulated morphology changes [72]
(Figure 3). RvE1’s counter-regulatory actions on human platelets
were calcium independent since RvE1 alone did not stimulate
intracellular calcium nor did it block ADP-stimulated calcium
mobilization[72],adirectconsequenceofP2Y1 signalling.Using
a recombinant overexpressing β-arrestin/P2Y12 system, transient
transfection of ChemR23 or mock indicated that RvE1 counter-
regulatory actions of P2Y12 signals were ChemR23 dependent
[72].
In addition to platelets, VMSCs (vascular smooth muscle cells)
also regulate the maintenance of vascular homoeostasis and when
aberrantly activated via inﬂammatory mediators such as hsCRP
(high-sensitivity C-reactive protein) can lead to cardiovascular
complications such as PAD (peripheral arterial disease) [77].
Exogenous application of human CRP to VSMCs derived from
Figure 3 RvE1 has protective actions on human platelets
Aspirin acetylated COX-2 in vascular endothelial cells contributes to the formation of RvE1
that stereoselectively generates 18R-hydroperoxy-EPE [18R-H(p)EPE]. 18R-HEPE is further
converted via sequential actions of leucocyte 5-LOX, leading to formation of RvE1. RvE1 acts
directly on human platelets to reduce ADP-stimulated platelet aggregation, TX generation,
P-selectin mobilization and actin polymerization in a calcium-independent manner. RvE1
counter-regulation of ADP activation is ChemR23 dependent.
human saphenous vein increased PDGF (platelet-derived growth
factor)-stimulated chemotaxis in a PDGFRβ (PDGF receptor
β)-dependent fashion [78]. The migration of VSMCs is a
characteristic feature of atherosclerotic lesion formation and
neointima formation following arterial injury and vein bypass
grafting. In a recent investigation, RvE1 decreased PDGF-
stimulated VSMC chemotaxis as well as PDGFR activation
[79]. Of note, ChemR23 is expressed on the VSMCs which
may account for its actions. Hence RvE1’s selective actions on
leucocytes in whole blood, platelets and VSMCs all point to its
potential protective role in the cardiovascular arena.
Failed resolution programmes? Implications for cardiovascular
diseases
Cardiovascular diseases are the number one cause of death
in the Western world [80]. Atherosclerosis, as an example, is
widely viewed as a chronic inﬂammatory disease characterized
by the excessive recruitment and activation of peripheral
blood mononuclear cells, such as monocytes and T-cells [81].
Monocytes differentiate into macrophages within the plaque
milieu and attempt to clear excess oxidized lipoproteins and
cholesterol from the tissue. This precipitates the generation of
lipid-ladenfoamcellsthatfailtoclearfromtheplaque,continueto
secrete pro-inﬂammatory mediators and eventually undergo post-
apoptotic secondary necrosis [82]. Emerging evidence highlights
that atherosclerosis could be viewed as failed resolution of
inﬂammation [82].
Given the central role of macrophage efferocytosis in
resolution, new evidence suggests that defective clearance of
plaque macrophages may underlie the progression of advanced
atherosclerotic lesions, characterized by macrophage necrosis
[83]. Peritoneal macrophages isolated from obese-diabetic
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Figure 4 Hypothetical scheme for RvE1/ChemR23-dependent signalling in human macrophages
The scheme outlines the key phosphorylation-signalling components with RvE1 and the points of inhibitor action in this system. Inset, representative immunoﬂuorescence of human macrophages
phagocytosis of opsonized FITC-zymosan (see [22] for details).
mice crossed with [LDLR LDL (low-density lipoprotein)-
receptor]deﬁcientmice(LDLR
−/−)displaydefectsintheirability
to phagocytose apoptotic cells [83]. Moreover, defective phago-
cytosis and clearance of apoptotic cells was observed in advanced
atherosclerotic lesions from these mice. Interestingly, saturated
fatty acids (e.g. palmitic and stearic) are increased in obese mice
relativetoendogenousω−3fattyacidsandwereimplicatedinde-
fective macrophage efferocytosis. Accordingly, supplementation
ofω−3fattyacidsEPAandDHAreverseddeﬁcitsinmacrophage
efferocytosis in obese/LDLR
−/− mice [83]. These ﬁndings
underscore that progression of chronic inﬂammatory diseases
could result in part because of impaired resolution and implicates
a protective role for endogenous lipid mediator pathways.
Interestingly, mice lacking both 12/15-LOX (lipoxygenase)
and apoE (alipoprotein E) display exacerbated atherosclerotic
lesion formation compared with apoE-null mice [84]. Targeted
macrophage-speciﬁc overexpression of 12/15-LOX protected
from lesion development. Importantly, 12/15-LOX gene dosage
correlated with LXA4 formation in isolated macrophages, as
well as the production of 17-hydroxyDHA, a marker of the
D-series resolvin biosynthetic pathway. Both lipoxins and
resolvins display potent actions on isolated macrophages
and endothelial cells, regulating production of pro-inﬂammatory
cytokines/chemokines and adhesion receptors [VCAM (vascular
cell adhesion molecule)-1 and P-selectin] [84]. Notably, LXA4
and RvD1 each enhance macrophage phagocytosis of apoptotic
cells. These results corroborate earlier ﬁndings in rabbits
demonstrating the atheroprotective effect of macrophage-speciﬁc
transgenicoverexpressionof15-LOX[85].Theanti-inﬂammatory
proresolving role of this pathway was independently conﬁrmed
in murine models of arthritis and ocular injury [86–88]. Hence
the enzymes involved in the active biosynthesis of SPMs
are critical for homoeostasis. Further investigation of direct
SPM actions in cardiovascular diseases, such as atherosclerosis
where macrophages play a crucial role [82] would be of interest.
RESOLVIN E1 SIGNALLING IN MACROPHAGES
Macrophageshaveseveralphenotypesandtheiractionscaneither
orchestrate inﬂammation or mediate resolution. Non-phlogistic
(i.e. non-fever-causing) recruitment of monocytes [89] and
phagocytosis by macrophagesis the hallmark of tissue resolution.
Hence it was of interest to further examine RvE1/ChemR23
signalling in macrophages. Figure 4 illustrates that RvE1-
exposed human macrophages activate a pathway recently
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identiﬁed which exhibits intense rS6 (ribosomal S6 protein)
phosphorylation [22]. RvE1-enhanced rS6 phosphorylation was
reducedwithwortmannin[aninhibitorofPI3K(phosphoinositide
3-kinase)],rapamycin[amTOR(mammaliantargetofrapamycin)
inhibitor] and PD98059 [an ERK (extracellular-signal-regulated
kinase) inhibitor]. In contrast, SB203580 [a p38 MAPK
(mitogen-activated protein kinase) inhibitor] and Bim [a PKC
(protein kinase C) inhibitor] did not dramatically reduce the
phosphorylation of rS6 [22].
rS6, a part of the small ribosomal subunit involved in
translation, is known as a phospho-protein stimulated with
growth factor or hormones [90]. It is also known that rS6 is
a major substrate of p70S6K, a kinase downstream of PI3K
(phosphoinositide 3-kinase)/Akt as well as Raf/ERK signal
transductions. When rS6 is phosphorylated by p70S6K, the cells
are undergoing growth [90]. There is the same motif, in which
phospho-Akt (S) antibody recognized phosphorylation, from rS6
phosphorylated sites (Ser
235 and Ser
236) [91].
To investigate RvE1/ChemR23-dependent rS6 phosphoryla-
tion, an anti-ChemR23 antibody (a competitor for receptor
binding), PD98059 and rapamycin were investigated and each
signiﬁcantlyreducedrS6phosphorylationtothebaselinevalue.In
contrast, isotype control IgG3κ, used as a negative control for the
anti-ChemR23antibody,didnotmodulatethephosphorylation.In
additiontoenhancedphagocytosisbymurinemacrophagesinvivo
[12]andinvitro[92],RvE1alsoenhancedphagocytosisinhuman
macrophages (Figure 4). Again, the anti-ChemR23 antibody, the
inhibitors PD98059 and rapamycin each signiﬁcantly reduced
phagocytizing cells to baseline. This reduction was not observed
with the IgG3κ antibody, which was used as a control for the anti-
ChemR23 antibody. These phosphorylation-signalling pathways
identiﬁed for RvE1 receptor–ligand interactions underscore the
importance of endogenous proresolving agonists in resolving
acute inﬂammation. Together, RvE1 acts on selective cellular
targets for the maintenance of homoeostasis (Figure 5).
SPM RECEPTOR-MEDIATED CIRCUITS
Mapping temporal changes of miRNAs (microRNAs) during
inﬂammation and resolution in vivo
The resolution of acute inﬂammation is a highly regulated
process controlled by soluble (e.g. cytokines, chemokines and
lipid autacoids) as well as cell-associated receptors and growth
factors [14,93,94]. An emerging line of investigation indicates
that many processes, at cellular, organ and systems level, are
ﬁnely tuned by miRNAs [95]. miRNAs are small (22–24 nt)
non-coding RNA sequences that act primarily as translational
repressors of gene transcripts by interacting with their 3
 
UTR (untranslated regions) [96], reviewed in [97]. miRNAs
are involved in many physiological and pathological processes
including several cancers [95] and in the immune response [98].
Previously, we sought evidence for miRNA involved in
the resolution of zymosan-stimulated inﬂammation. RvD1 and
other SPMs regulate cytokine production [84], NF-κB (nuclear
factor κB) and pro-inﬂammatory eicosanoids (e.g. certain
prostaglandins and leukotrienes) [24], and miRNAs are involved
inregulatingthesemolecules[98].InordertoinvestigatemiRNAs
involved in self-limited inﬂammation and resolution, zymosan
A-stimulated self-limited peritonitis was carried out. Resolution
indices [3] were calculated in order to obtain the peak of
inﬂammation (deﬁned by the peak in PMN numbers) compared
with the time point in which the mice were in the resolving phase
(when PMN numbers reach half maximum). Characterizing the
resolution phase allows for the investigation of temporal changes
Figure 5 RvE1’s selective cellular targets and actions
Scheme of RvE1’s actions on speciﬁc cells.
in miRNA expression in exudates collected 4, 12 and 24 h post
zymosan challenge, which correspond with the onset, maximum
and resolution phases respectively, was monitored.
Among the few miRNAs highly expressed in the exudates at
12 h, miR-21, miR-146b, miR-208 and miR-203 displayed >2.5-
fold change when compared with 4 h [99]. Conversely, a large
group of miRNAs showed lower expression between 12 and 4 h
time points such as miR-142-5p and miR-3p, miR-219 and miR-
302d, indicating temporal changes in miRNA regulation during
inﬂammation and resolution. Hence miRNAs are differentially
regulated during inﬂammation and resolution. The next question
iswhethertheSPMRvD1furthermodulatesthesemiRNAsduring
self-limited inﬂammation and resolution.
RvD1-regulated miRNAs: a temporal regulation in vivo
RvD1 is biosynthesized during resolution [14], regulates further
PMN inﬁltration and stimulates non-phlogistic macrophage
phagocytic activity [24,27,84,100]. Resolution indices were
used here to deﬁne and pinpoint RvD1 actions in resolution.
Administration of RvD1 resulted in a signiﬁcant decrease in
leucocyte inﬁltration at 12 h, consistent with RvD1-deﬁned
actions [14,100]. miRNA array analysis showed RvD1 increased
levelsofmiR-146b,miR-142-3p,miR-5pandmiR-219inexudate
cells at the peak of PMN inﬁltration. RvD1 slightly down-
regulated miR-21, miR-203, miR-208 and miR-302d at this
time point. Interestingly RvD1-treated mice had a signiﬁcant
reduction in expression levels of all miRNAs analysed at 48 h,
with the exception of miR-302d that was not regulated in RvD1-
treated mice at this time point. These ﬁndings suggest that RvD1
temporally controls speciﬁc sets of miRNAs in exudates in vivo.
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Figure 6 Resolution circuitry
(A) Scheme of RvD1 miRNA circuit. RvD1 is generated within inﬂammatory exudates and acts directly on selective cell types such as monocytes/macrophages. RvD1 actions are via its receptors,
ALX or GPR32 to regulate miRNAs, transcription factors, gene expression and cellular function. (B) RvD1 down-regulates miR-219 via its receptors ALX and GPR32, which leads to less 5-LOX
protein (C) and reduced LTB4 generation (D). Adapted from [99]. ∗P <0.05 compared against vehicle; #P <0.05 compared against mock.
RvD1 regulation of miRNAs, genes and transcription factors in
human macrophages and monocytes
Human macrophages were investigated because they are
key players in innate immunity and resolution. Regulatory
actions of RvD1 using human macrophages overexpressing the
speciﬁc RvD1 receptors ALX/FPR2 and GPR32 [24]
demonstrated that RvD1 down-regulated miR-21, miR-146b and
miR-219, whereas it increased levels of miR-208 and miR-
302d. These results indicate that RvD1 regulates speciﬁc miRNA
molecules via its interactions with speciﬁc RvD1 receptors.
The target genes regulated by miR-146b, miR-208 and miR-
219 were assessed. Overexpression of miR-146b in human
macrophagesresultedinsigniﬁcantdown-regulationoftranscripts
ofseveralcytokines,chemokinesandtheirreceptors,suchasIL-8,
IL-10, IL-12 receptor β2, CCR3 (chemokine CC motif receptor
3),IFN(interferon)α1andβ1,andmembersoftheIL-1familyto
name a few. Also, genes involved in the innate immune response
and pathogen recognition, i.e. S100A12, LBP (lipopolysaccharide
binding protein), CRP, C8a (complement component 8 α
polypeptide), TLR (Toll-like receptor) 9, TLR10, PGLYRP
(peptidoglycan recognition protein) 1 and PGLYRP2, were
signiﬁcantly reduced in macrophage miR-146b. Additionally,
there were reductions in the mRNAs for CHUK (conserved
helix–loop–helix ubiquitous kinase) also known as IKKα [IκB
(inhibitory κB) kinase α], TRAF6 [TNF (tumour necrosis
factor)-receptor-associated factor 6], nitric oxide synthase 2,
PTAFR (platelet-activating factor receptor) and CD40. In miR-
208a-overexpressing macrophages, reductions were obtained for
mRNAs encoding for CD14, CD40L (CD40 ligand), PTGIR
(prostaglandin I2 receptor), TBXA2R (TXA2 receptor) and
PDCD4(programmedcelldeath4),atumoursuppressormolecule
that regulates NF-κB activation and decreases IL-10 production
[101].Ofnote,miR-219overexpressiongavesigniﬁcantreduction
in CD14, TNF receptor II, phospholipase Cγ2 and AA 5-
LOX. Further investigation of miR-219 overexpression yielded
decreased 5-LOX protein and leukotriene production (Figure 6).
Since many of the target genes of RvD1-regulated miRNA
networks were involved in TFs (transcription factor) regulation, a
panel of TFs with human monocytes to gain insight into potential
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translation was screened. Of interest, RvD1 signiﬁcantly reduced
nucleartranslocationofNF-κBandSmadcomparedwithvehicle.
RvD1 reduced TNF-α induced phosphorylation of IκB, a critical
step in NF-κB activation and nuclear translocation. Therefore
these results suggest that RvD1 regulates the NF-κB pathway in
human monocytes.
A miRNA signature of resolution within resolving self-limited
inﬂammatory exudates was mapped. The proresolving mediator
RvD1regulatedresolutionindicesandcontrolledspeciﬁcmiRNA
expression in exudates in vivo that were also activated via
recombinant receptors ALX/FPR2 and GPR32 regulating miR-
146b, miR-208a and miR-219 (ex vivo). These results establish a
novel RvD1-G-protein-coupled receptor-dependent miRNA axis
in resolution circuits (Figure 6).
CONCLUDING REMARKS AND FUTURE DIRECTIONS
The formation of endogenous autacoids derived from PUFAs
and speciﬁcally dietary ω−3 fatty acids may explain in part the
well-known essential roles of the ω−3 ﬁsh oils in human health
and disease [102]. ω−3-derived SPMs temporally regulate the
resolution of inﬂammation via systematic changes in speciﬁc cell
types, their activity and counter-regulation of pro-inﬂammatory
signalsuponperturbationorchallengeoftheorganand/ortissues.
SPMs are endogenous lipid mediators that are enzymatically
biosynthesized and act on selective cellular targets via speciﬁc 7-
TMsforbioaction.UncoveringthesenovelSPMsemboldenedthe
notion that agonists can quiesce the propagation of inﬂammation
while stimulating resolution. SPMs were the ﬁrst mediators
demonstrated to actively promote resolution, but since their
discovery many laboratories have found that other mediators
have proresolving actions including peptides [26]. As reviewed
herein, SPMs have speciﬁc cellular targets of shorter duration
in the peripheral blood such as PMNs and platelets, where the
SPMs evoke their actions within seconds of their formation, as
well as receptor–ligand interactions that stimulate changes in
speciﬁc miRNA of longer duration (i.e. hours) to return tissues
to homoeostasis. Proresolving agonists open a new terrain for
identifyingendogenousbiochemicalpathwaysthatexploitnatural
mechanisms operating in vivo to terminate the inﬂammatory
response and tissue injury.
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